by John Conrad | Nov 20, 2025 | iBIO News
Illinois’ life sciences industry is entering one of the most promising periods in its history. Today, more than 93,000 Illinoisans work in biosciences, earning an average annual wage of $153,000—a figure that speaks not only to the sophistication of these roles but...
by John Conrad | Nov 20, 2025 | Member News
It was exciting to see Dimension Bio featured in Fast Company this week — a national spotlight that underscores just how far this Chicago-born biotech has pushed the boundaries of regenerative medicine. The profile traces the company’s journey from its early work in...
by John Conrad | Nov 20, 2025 | Member News
Abbott confirmed a $21 billion deal to acquire Exact Sciences, instantly becoming one of the biggest moves in diagnostics in years. Abbott will pay $105 per share in cash, a 51% premium, sending Exact’s stock sharply higher for a second straight day. The deal gives...
by John Conrad | Nov 17, 2025 | iBIO News
Even with Washington hitting the pause button during the federal shutdown, this month’s GBG Report still surfaced 78 new non-dilutive funding opportunities, notices of special interest, and RFIs across the life sciences landscape. That’s a slimmer number than usual —...
by John Conrad | Nov 10, 2025 | iBIO News
The Illinois life sciences community gathered last Thursday evening at The Salt Shed’s Three Top Lounge for the 2025 iBIO iCON Awards. The event brought together researchers, CEOs, entrepreneurs, investors, policymakers, educators, and community partners for a night...
by John Conrad | Oct 28, 2025 | iBIO News
iBIO (Illinois Biotechnology Innovation Organization) is proud to announce the winners of the 2025 iCON Awards, recognizing extraordinary leaders who have driven innovation and growth within Illinois’s thriving life sciences community. Now in its 13th year, the...
by John Conrad | Oct 10, 2025 | Policy News
There’s been a lot of misinformation circulating about the 340B Drug Pricing Program and HB2371 in Illinois. Let’s separate fact from fiction. We’ve been hearing some wild claims from hospital lobbying groups about what will happen if HB2371 doesn’t pass....
by John Conrad | Sep 26, 2025 | Policy News
John Conrad, President and CEO of the Illinois Biotechnology Innovation Organization (iBIO) issued the following response regarding proposed 100% import duties on proprietary pharmaceutical products: “iBIO supports expanding domestic life sciences manufacturing....
by John Conrad | Sep 10, 2025 | Grants, iBIO News
G2G Consulting has released the September Government Bioscience Grants (GBG) report for iBIO members through our exclusive partnership, featuring 104 non-dilutive funding opportunities across biotechnology and life sciences. Members can join G2G’s Monthly GBG...
by John Conrad | Aug 21, 2025 | Policy News
iBIO has joined AdvaMed and 65 other organizations in urging the Centers for Medicare and Medicaid Services (CMS) to create a streamlined pathway for Medicare patients to access FDA-authorized breakthrough medical technology. The coalition’s letter to CMS...
